Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Polyrizon Ltd. ( (PLRZ) ) has shared an update.
On November 6, 2025, Polyrizon Ltd. announced positive in-vitro results for its PL-16 Viral Blocker, a nasal gel formulation that demonstrates broad-spectrum viral blocking efficacy. The product acts as a reversible physical barrier against respiratory viruses, including H1N1, without cytotoxicity, highlighting its potential as a safe, non-pharmacological nasal protection product. This development could enhance Polyrizon’s position in the biotechnology industry by offering a unique solution for respiratory protection.
More about Polyrizon Ltd.
Polyrizon Ltd. is a biotechnology company focused on developing innovative intranasal products using its proprietary Capture & Contain (C&C) platform. The company specializes in creating nasal sprays that form a hydrogel-based barrier to protect against viruses and allergens. Polyrizon is also working on advancing its technology for drug delivery through nasal sprays.
Average Trading Volume: 1,145,508
Technical Sentiment Signal: Strong Sell
Current Market Cap: $5.89M
See more insights into PLRZ stock on TipRanks’ Stock Analysis page.